MedPath

Recombinant Super-Compound Interferon

Generic Name
Recombinant Super-Compound Interferon
Drug Type
Biotech
Background

Recombinant super-compound interferon (rSIFN-co) is a recombinant version of interferon alpha with modified spatial configuration. This interferon has antiviral and antitumor activity.

rSIFN-co Among Healthy Subjects and Subjects With Mild or Asymptomatic COVID-19

Phase 2
Completed
Conditions
COVID-19
SARS-CoV-2 Infection
Interventions
Drug: Placebo Nasal Spray
First Posted Date
2022-08-03
Last Posted Date
2025-02-25
Lead Sponsor
Sichuan Huiyang Life Science and Technology Corporation
Target Recruit Count
188
Registration Number
NCT05485584
Locations
🇵🇭

GreenCity Medical Center, San Fernando, Central Luzon, Philippines

🇵🇭

Medical Center Manila, Manila, Philippines

Study of rSIFN-co for Patients With Advanced Solid Tumors

Phase 1
Terminated
Conditions
Malignancies Including Melanoma, Kidney, Lung, Colorectal, Prostate, Neuroendocrine Tumor
Interventions
First Posted Date
2015-06-08
Last Posted Date
2025-02-25
Lead Sponsor
Sichuan Huiyang Life Science and Technology Corporation
Target Recruit Count
7
Registration Number
NCT02464007
Locations
🇺🇸

HealthPartners Institute, Saint Paul, Minnesota, United States

🇺🇸

Rush University Medical Center, Chicago, Illinois, United States

🇺🇸

Mayo Clinic, Phoenix, Arizona, United States

and more 1 locations

A Study of rSIFN-co in Subjects With Advanced Solid Tumors

Phase 1
Completed
Conditions
Melanoma
Carcinoma, Non-Small-Cell Lung
Carcinoma, Renal Cell
Colon Cancer
Carcinoma, Hepatocellular
Interventions
First Posted Date
2015-03-13
Last Posted Date
2019-09-27
Lead Sponsor
Sichuan Huiyang Life Science and Technology Corporation
Target Recruit Count
42
Registration Number
NCT02387307
Locations
🇸🇬

National Cancer Centre Singapore, Singapore, Singapore

© Copyright 2025. All Rights Reserved by MedPath